NCT06508775 - Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 5, 2024

Primary Completion Date

December 31, 2040

Study Completion Date

December 31, 2040

Conditions

Melanoma Stage IIIB-cell Non Hodgkin LymphomaPediatric ALLChildhood Non-Hodgkin LymphomaAcute Lymphatic LeukemiaChronic Lymphatic LeukemiaMelanoma Stage IV

Interventions

BIOLOGICAL

MB-CART19.1

Assessment of long-term safety and efficacy of MB-CART19.1 treatment.

BIOLOGICAL

MB-CART20.1

Assessment of long-term safety and efficacy of MB-CART20.1 treatment.

BIOLOGICAL

MB-CART2019.1

Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.

Trial Locations (4)

37075

RECRUITING

Universitätsmedizin Göttingen, Göttingen

48149

RECRUITING

Universitätsklinikum Münster, Münster

50937

RECRUITING

Universitätsklinikum Köln, Cologne

97080

RECRUITING

Universitäts-Kinderklinik Würzburg, Würzburg